Johnson & Johnson (JNJ) News

Johnson & Johnson (JNJ)

Today's Latest Price: $145.24 USD

0.16 (0.11%)

Updated Oct 23 7:00pm

Add JNJ to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter JNJ News Items

JNJ News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest JNJ News From Around the Web

Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

Low infection rates could extend data readouts in large-scale COVID-19 trials

Falling COVID-19 infection rates, especially among adults at least 55 years old, are good news/bad news for public health and vaccine developers. The negative implications of higher infection rates are self-evident for the overall population but are a narrowly defined positive for vaccine makers considering the shorter amount of time...

Seeking Alpha | October 3, 2020

U.S. Hydrogel Dressing Market To See Record Break Revenue $258 million By 2022 | 3M Company and Johnson & Johnson

UPDATE AVAILABLE ON-DEMAND The report on the U.S. hydrogel dressing market highlights that the market is expected to reach $258 million in 2022, growing at a CAGR of 7.0% from 2016 to 2022. The report offers the current market size and

OpenPR | October 2, 2020

J&J wins injunction against accused counterfeit seller

Johnson & Johnson and its Ethicon unit have won a preliminary injunction against a Chicago company accused of selling counterfeit and expired Ethicon surgical devices.

Reuters | October 2, 2020

Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford's COVID-19 Vaccine Trials are Entering the Final Stage of Development

DUBLIN, Oct. 2, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the vaccine industry "COVID-19 Vaccine Trials are Entering the Final Stage of Development" Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the…

PR Newswire | October 2, 2020

Experts weigh in after poll shows only 2 in 10 Americans will take COVID-19 vaccine Trump deems safe

Filed under: News , Drugs & Medicine , Science & Tech Despite positive news from both Moderna and Johnson & Johnson this week on their vaccine trials, a new poll from Axios-Ipsos found that “barely two in 10 Americans” would take a COVID-19 vaccine if President Trump declared it safe. In comparison, 62 percent said they would take it if their doctors declared it safe and 54 percent would take it if the Food and Drug Administration deemed it safe. Read more… Permalink | Email this | Linking Blogs | Comments

AOL | October 1, 2020

Impact of Covid-19 on Gastrointestinal Devices Market – New Business Opportunities and Investment Research Report 2027 | Covidien Ltd, Boston Scientific Corporation, Johnson & Johnson, CONMED Corporation

The global gastrointestinal devices market is forecast to reach USD 13.54 Billion by 2027, according to a new report by Reports and Data. The gastroenterology is the branch of medical science pertaining to the health of the digestive system, or the gastrointestinal

OpenPR | October 1, 2020

Ophthalmic Devices Market Checkout the Unexpected Future 2027 | Key Players - Bausch + Lomb, Johnson & Johnson, Alcon, Topcon, Carl Zeiss Meditec

Global Ophthalmic Devices Market has been brewing up and influencing the international economy with respect to revenue, growth rate, sale, market share, and size. The Global Ophthalmic Devices Market research report provides a rational explanation to the reader to understand

OpenPR | October 1, 2020

Will October Be A Reachable Goal For A Vaccine?

Despite slim chances that the COVID-19 vaccine will see the light of the public day in October, Pfizer Inc. (NYSE: PFE ) is getting our hopes up. According to SVB Leerink, a Wall Street firm, even though Moderna Inc (NASDAQ: MRNA ) and Pfizer began their trials on the same day, Pfizer's is built for speed. As a reminder, there are four vaccines undergoing the final stage of U.S. clinical trials and a fifth by Maryland-based Novavax, Inc. (NASDAQ: NVAX ) on the way. Although the final stage of clinical trials in the U. S. will begin in October Phase 3 in the UK is well underway as of September 25 th . The four other candidates besides Moderna and Pfizer are Johnson & Johnson (NYSE: JNJ ) and AstraZeneca plc (NYSE: AZN ). But unlike Johnson & Johnson and AstraZeneca which have said they w...

Benzinga | October 1, 2020

J&J finalizes Momenta Pharma buy (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) has completed its $6.5B acquisition of Momenta Pharmaceuticals at $52.50 per common share. The deal was announced in August.

Seeking Alpha | October 1, 2020

Global Digital Dose Inhaler Market Report Covers Growing Strategies Used By Top Key Players || Johnson and Johnson(Ethicon), Novartis International AG, Propeller Health, AstraZeneca Plc

The motive of this strategic research report entitled Global Digital Dose Inhaler Market Which offers company accounts, industry investors, and industry members with consequential insights to enable them to make reliable strategic decisions regarding the opportunities in the global Digital

OpenPR | September 30, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5124 seconds.